Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer

Abstract Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase T cell infiltration into the tumor, and oral cyclophospha...

Descripción completa

Detalles Bibliográficos

Autores principales:	Spencer R. Rosario, Mark D. Long, Shanmuga Chilakapati, Eduardo Cortes Gomez, Sebastiano Battaglia, Prashant K. Singh, Jianmin Wang, Katy Wang, Kristopher Attwood, Suzanne M. Hess, AJ Robert McGray, Kunle Odunsi, Brahm H. Segal, Gyorgy Paragh, Song Liu, Jennifer A. Wargo, Emese Zsiros
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2024-12-01
Colección:	Nature Communications
Acceso en línea:	https://doi.org/10.1038/s41467-024-54565-8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!